WOBURN, Mass.--(BUSINESS WIRE)--We are pleased to announce that Aphios Pharma LLC will host a live webinar followed by Q&A on the science and technology of cannabis as a medicine.
WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation announced today that it has been granted US Patent No. 11,234,932 for treating HIV latency towards an HIV cure.
WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation today announced that it has been granted Chinese Patent No. 201811111996.8 by China National Intellectual Property Administration on October 26, 2021. The patent entitled, “Bryoid Compositions, Methods of Making and Use Thereof,” covers novel composition of matter of the novel Bryoid, Bryostatin-23 and use for the treatment of Alzheimer’s disease and other neurodegenerative diseases, virus latency diseases such as HIV and Herpes, cancers and glaucoma.
WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation announced today that it has been granted United States Patent No. 10,954,248 entitled “Bryoid Compositions, Methods of Making and Use Thereof.” This patent is part of a family of Aphios patents in Europe (Patent No. 2,925,315, Jan. 16, 2019), Japan (Patent No. 6,440,628, Nov. 30, 2018), Hong Kong (Patent No. HK1,216,891, Nov. 22, 2019), and China (Patent No. ZL201380069328.2, Oct. 19, 2018).